Navigation Links
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Date:11/7/2007

Golimumab Achieved Primary and Major Secondary Endpoints in the Largest

Phase 3 Biologic Trial Completed to Date in Psoriatic Arthritis

BOSTON, Nov. 7 /PRNewswire/ -- Patients with active psoriatic arthritis receiving monthly subcutaneous (SC) injections of golimumab (CNTO 148) experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest Phase 3 biologic study ever completed in subjects with psoriatic arthritis. Findings presented at the American College of Rheumatology (ACR) Annual Scientific Meeting showed that at week 14 of the 405-patient study in subjects with active psoriatic arthritis, 51 percent of patients receiving golimumab 50 mg and 45 percent of patients receiving golimumab 100 mg experienced at least 20 percent improvement in arthritis signs and symptoms (ACR 20) compared with 9 percent of patients receiving placebo (P < 0.001 for both comparisons). Golimumab-treated patients maintained significant improvements in arthritis through week 24 and also showed substantial and sustained improvements in skin and nail psoriatic disease (as measured by a 75 percent reduction in Psoriasis Area and Severity Index [PASI 75] in patients with baseline body surface area with psoriasis of at least three percent, and the Nail Psoriasis Severity Index [NAPSI]).

Golimumab, Centocor Inc. and Schering-Plough Corporation's next-generation human anti-tumor necrosis factor (TNF)-alpha monoclonal antibody, is currently in the most comprehensive Phase 3 development program to date for an anti-TNF- alpha biologic therapy. With ongoing studies for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, golimumab is being studied as a monthly SC injection and an every twelve-week intravenous (IV) infusion (approximately 30-minutes) therapy.

"The availability of treatments that target TNF-alpha have dramatically changed rheumatologists' ap
'/>"/>

SOURCE Centocor Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
3. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
4. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. Positive Kuvan(TM) Pivotal Phase 3 Trial Results Published in The Lancet
8. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
9. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... 2013  Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ... the Deutsche Bank Health Care Conference to be held ... Adrian Adams , Chief Executive Officer ... the Company and its product pipeline at 12:00 p.m. ... (Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO ) The presentation will ...
(Date:5/23/2013)... 24, 2013 3SBio Inc. (NASDAQ: ... leading China -based biotechnology company ... products, announced today that, at an extraordinary general ... voted in favor of the proposal to authorize ... of merger dated February 8, 2013, among Decade ...
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
Breaking Medicine Technology:Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 2Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 3Auxilium Pharmaceuticals, Inc. To Present At The Deutsche Bank Health Care Conference 43SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3
(Date:5/24/2013)... -- Low-income, minority parents have more realistic views ... open to vaccinating their daughters against the cervical ... contends. Conversely, white, middle-class parents are more ... according to researchers from the Boston University School ... an HPV-related cancer each year, many of which ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 According to a ... Facebook: Social Media Leads to Spikes in Plastic Surgery ... is a growing prevalence of facial plastic surgery ... These people have become keenly aware of the need to ... such as Facebook, Google and even Skype's video chat feature ...
(Date:5/24/2013)... York, New York (PRWEB) May 24, 2013 ... 101 Mobility® is a leading nationwide sales, ... solutions for both consumer and commercial applications. The ... vertical platform lifts, vehicle lifts for mobility devices, ... among others. 101 Mobility operates over 30 locations, ...
(Date:5/24/2013)... 24 (HealthDay News) -- Two out of five medical ... new study found. The study authors, from Wake ... a significant barrier to the treatment of obesity. They ... is necessary to improve care for the millions of ... affect clinical care and the doctor-patient relationship, and even ...
(Date:5/24/2013)... A new investigational device - the Helio System (TF-FA) ... Transcatheter Heart Valve was successfully deployed in all four ... use in high-risk aortic insufficiency reported at EuroPCR 2013. ... to help stabilise the SAPIEN XT valve for patients ... are captured between the transcatheter heart valve and the ...
Breaking Medicine News(10 mins):Health News:Low-Income, Minority Parents More Open to HPV Vaccine for Girls, Study Says 2Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Cortec Closes Equity Transaction with 101 Mobility 2Health News:Many Medical Students Have Anti-Fat Bias, Study Finds 2Health News:Feasibility trial reports deployment of new device for TAVI in aortic insufficiency 2
... approved at annual shareholder meeting , , SALT LAKE CITY, ... overwhelmingly approved the renaming of Sonic Innovations, Inc. to Otix Global, ... meeting May 7, 2009. The company has filed the appropriate ... effect on June 15, 2009. , , ...
... HUNTINGTON BEACH, Calif., June 8 Forterus Inc. (Pink Sheets: ... alcohol rehabilitation and a variety of other healthcare services, with ... renewing an offer to provide free outpatient treatment to military ... or Afghanistan war zones within the last five years. , ...
... , ... 4.0 allows help desk staff to administer and remotely control Windows computers. Unlike similar ... to find computers With its unique search engine. It can find the computer you ... , ...
... ARBOR, Mich. Women are under-represented in clinical cancer ... study by researchers at the University of Michigan Comprehensive ... particular types of cancer among women, studies included a ... analysis looked specifically at studies of cancer types that ...
... A ... in facelift surgery and what benefits these techniques have for the patient. , ... Manchester, UK (PRWeb UK) 07 June, 2009 ... clinics / providers of cosmetic surgery than ever before. As a result there is an ...
... can do a lot to keep kids safe, experts say, , ... to be), youngsters are probably going to be spending less ... doing cannonballs. , It,s all fun and games -- until someone ... warn child safety experts. , Though many injuries amount to little ...
Cached Medicine News:Health News:Otix Global, Inc. to Become Parent Company of Sonic Innovations, Inc. 2Health News:Otix Global, Inc. to Become Parent Company of Sonic Innovations, Inc. 3Health News:Forterus Inc. Announces Free Outpatient Treatment to Military Veterans Back from War Zones 2Health News:Windows XP, Vista, and Windows 7 Compatible Remote Control 4.0 Beta Released by IntelliAdmin, LLC 2Health News:Women under-represented in cancer research, U-M study finds 2Health News:Latest Developments In Facelift Surgery - Expert Opinion by Mr James Murphy 2Health News:Latest Developments In Facelift Surgery - Expert Opinion by Mr James Murphy 3Health News:Summer Fun Need Not Be Hazardous 2
... is the most versatile orthopedic/trauma ... designed for both lower body ... an integrated shoulder attachment. The ... operating table for your most ...
... is restricted. Due to its excellent drive ... every situation. For many complicated surgery positions, ... on the JUPITER during the induction to ... the high level of stability of JUPITER ...
... universal operating table for any application. ... for unlimited C-arm access. High stability ... neurosurgical and cardiovascular procedures. An extension ... support can easily be attached for ...
... The Medstone Pro-2000BT carbon fiber ... unobstructed imaging for urology, brachytherapy, gynecology, ... other procedures. The open design allows ... movements include up to 16-inch elevating ...
Medicine Products: